Treatment program for cannabis use disorder
Gender and Sex Hormone Influences on Cannabis Use Disorder Remission
This study is testing an 8-week treatment program that helps adults who want to cut down on their cannabis use through counseling and therapy sessions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 224 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of South Carolina Academic / other |
| Locations | 1 site (Charleston, South Carolina) |
| Trial ID | NCT04964739 on ClinicalTrials.gov |
What this trial studies
This study involves enrolling adults aged 18 and older who wish to reduce their cannabis use in an 8-week treatment program. Participants will receive counseling, including one goal-setting session with a therapist followed by seven weekly computerized cognitive-behavioral therapy sessions. Throughout the treatment, detailed assessments of cannabis use will be conducted, including biological tests and self-reports, along with daily electronic diaries to log cannabis use. Salivary samples will also be collected daily to analyze progesterone levels.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who meet the DSM-5 criteria for cannabis use disorder and are motivated to seek treatment.
Not a fit: Patients with significant psychiatric issues, other substance use disorders requiring higher care, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could help individuals effectively reduce their cannabis use and improve their overall well-being.
How similar studies have performed: Other studies have shown success with cognitive-behavioral therapy approaches for substance use disorders, indicating potential for positive outcomes in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willingness to participate in a research study (otherwise, will be referred to appropriate clinical services if seeking clinical care). 2. Meet current (within last 30 days) DSM-5 criteria for cannabis use disorder. 3. Submit a positive urine cannabinoid test during screening. 4. Interested in treatment for cannabis use disorder. Exclusion Criteria: 1. Significant or acutely unstable medical or psychiatric problems (i.e., psychosis, mania) that would contraindicate research procedures, interfere with safety, compromise data integrity, or preclude consistent study participation. 2. The presence of any substance use disorder requiring a higher level of care. 3. Significant risk of homicide or suicide. 4. Pregnant, trying to become pregnant, or breastfeeding.
Where this trial is running
Charleston, South Carolina
- Medical University of South Carolina — Charleston, South Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Rachel L Tomko, PhD — Medical University of South Carolina
- Study coordinator: Kevin Branson
- Email: bransonk@musc.edu
- Phone: 843-792-0493
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.